Showing 8 posts of 8 posts found.

AstraZeneca halts lung cancer trials amidst safety concerns

October 13, 2015
Manufacturing and Production AZD9291, AstraZeneca, MEDI4736, NSCLC, drug safety, durvalumab, interstitial lung disease, lung cancer, non-small cell lung cancer

AstraZeneca is stopping two trials of a combination of two of its pipeline cancer treatments, after reports that the pairing …


AstraZeneca and Peregrine in immuno-oncology collaboration

August 24, 2015
Research and Development AstraZeneca, Cancer, MEDI4736, Peregrine, Peregrine Pharmaceuticals, bavituximab, durvalumab, immunoncology, immunotherapy, oncology, tumours

AstraZeneca and Peregrine Pharmaceuticals will collaborate on a clinical trial to test two of the companies’ cancer treatments. The Phase …

AZ image

AstraZeneca lung drug shines on

June 1, 2015
Sales and Marketing ASCO, AZD9291, AstraZeneca, MEDI4736, NSCLC, Tafinlar

AstraZeneca’s investigational drug AZD9291 is continuing to impress, with results announced at cancer conference ASCO building on its previous ‘unprecedented’ …

Astrazeneca image

AstraZeneca eyes success in immuno-oncology combinations

May 14, 2015
Sales and Marketing ASCO, AZ, AstraZeneca, CTLA-4, MEDI4736

An investigational immuno-oncology drug combination from AstraZeneca has shown promise in its most recent trial, although concerns over its side …

MedImmune image

AstraZeneca signs immuno-oncology deal with UK firm

April 16, 2015
Research and Development, Sales and Marketing AstraZeneca, IMCgp100, MEDI4736, MedImmune, Oxford, immuno-oncology, immunocore, melanoma, tremelimumab

UK pharma and biotech firms AstraZeneca and Immunocore are teaming up to launch early-stage studies of potential new cancer treatments. …

astrazeneca image

FDA grants AstraZeneca immune drug orphan status

April 15, 2015
Sales and Marketing AstraZeneca, FDA, Iressa, MEDI4736, MedImmune, NSCLC, US, gefitinib, non-small cell lung cancer, tremelimumab

The US Food and Drug Administration has granted orphan drug designation to AstraZeneca’s anti-CTLA-4 monoclonal antibody tremelimumab for the treatment …

Medimmune image

MedImmune to work with biotech Advaxis on cancer

July 22, 2014
Research and Development, Sales and Marketing Advaxis, AstraZeneca, Cancer, MEDI4736, MedImmune, oncology, pd1

AZ’s MedImmune has entered into a clinical trial collaboration with US biotech firm Advaxis to help develop new cancer immunotherapies. …


AstraZeneca begins lung cancer trial

May 9, 2014
Research and Development, Sales and Marketing AstraZeneca, Cancer, MEDI4736, NSCLC, lung cancer

AstraZeneca, currently at the centre of a £63 billion bid from US giant Pfizer, has begun a late-stage trial of …

Latest content